Rese-cel, previously called CABA-201, is a CAR T-cell therapy that's designed to treat MS by depleting B-cells.

Switching therapies is a common part of multiple sclerosis management and may be considered for several reasons.

Subcutaneous ocrelizumab (SC OCR) was found to be safe for patients with relapsing and primary progressive multiple sclerosis ...

Contineum Therapeutics has concluded the targeted enrolment of 168 subjects in its Phase II trial of M1 receptor antagonist ...

In MS, immune system cells mistakenly attack myelin. With stem cell treatment, doctors use chemotherapy to destroy these existing immune cells. Then, they introduce the new stem cells, which are ...

Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in ...

Age is a major modifier of inflammatory CSF signatures in MS. This finding identifies novel biomarker candidates and potential therapeutic targets.

Published extended data from the phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting MS in the peer reviewed journal, Neurology® Neuroimmunology & Neuroinflammation, an official ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS).

The company is testing a fully human anti-CD3 monoclonal antibody, foralumab, in secondary progressive multiple sclerosis [SPMS] and Alzheimer’s disease [AD]. Trial results from a randomized ...